UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Current Concepts and Treatments of Schizophrenia

Molecules (Basel, Switzerland), 2018-08, Vol.23 (8), p.2087

2018

Volltextzugriff (PDF)

Multi-Target Approach for Drug Discovery against Schizophrenia

International journal of molecular sciences, 2018-10, Vol.19 (10), p.3105

2018

Volltextzugriff (PDF)

Overcoming Depression with 5-HT2A Receptor Ligands

International journal of molecular sciences, 2022-01, Vol.23 (1), p.10

2022

Volltextzugriff (PDF)

Screening and Structure-Activity Relationship of D2AAK1 Derivatives for Potential Application in the Treatment of Neurodegenerative Diseases

Molecules (Basel, Switzerland), 2022-03, Vol.27 (7), p.2239

2022

Volltextzugriff (PDF)

What are the challenges with multi-targeted drug design for complex diseases?

Expert opinion on drug discovery, 2022-07, Vol.17 (7), p.673-683

2022

Volltextzugriff (PDF)

Tight-binding model for exciton-polariton condensates in external potentials

Physical review. A, Atomic, molecular, and optical physics, 2013-09, Vol.88 (3), Article 033626

2013

Volltextzugriff (PDF)

Effects of small molecules on neurogenesis: Neuronal proliferation and differentiation

Acta pharmaceutica Sinica. B, 2024-01, Vol.14 (1), p.20-37

2024

Volltextzugriff (PDF)

Thermal behavior and determination of physicochemical properties of novel candidates for antipsychotic drugs

Journal of thermal analysis and calorimetry, 2024-07

2024

Volltextzugriff (PDF)

Experimental and computational structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles

Journal of molecular structure, 2021-12, Vol.1245, p.130998, Article 130998

2021

Volltextzugriff (PDF)

Development and Characterization of Novel Selective, Non-Basic Dopamine D2 Receptor Antagonists for the Treatment of Schizophrenia

Molecules (Basel, Switzerland), 2023-05, Vol.28 (10), p.4211

2023

Volltextzugriff (PDF)

Multi-targeted drug design strategies for the treatment of schizophrenia

Expert opinion on drug discovery, 2021-01, Vol.16 (1), p.101-114

2021

Volltextzugriff (PDF)

Current Approaches and Tools Used in Drug Development against Parkinson's Disease

Biomolecules (Basel, Switzerland), 2021-06, Vol.11 (6), p.897

2021

Volltextzugriff (PDF)

Funnel metadynamics and behavioral studies reveal complex effect of D2AAK1 ligand on anxiety-like processes

Scientific reports, 2022-12, Vol.12 (1), p.21192-14, Article 21192

2022

Volltextzugriff (PDF)

Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation

Journal of enzyme inhibition and medicinal chemistry, 2023-12, Vol.38 (1), p.2209828-2209828

2023

Volltextzugriff (PDF)

Synthesis, pharmacological and structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as multi-target ligands of aminergic GPCRs

European journal of medicinal chemistry, 2019-10, Vol.180, p.673-689

2019

Volltextzugriff (PDF)

Discovery and in vitro Evaluation of Novel Serotonin 5‐HT2A Receptor Ligands Identified Through Virtual Screening

ChemMedChem, 2024-07, Vol.19 (14), p.e202400080-n/a

2024

Volltextzugriff (PDF)

The Antipsychotic D2AAK1 as a Memory Enhancer for Treatment of Mental and Neurodegenerative Diseases

International journal of molecular sciences, 2020-11, Vol.21 (22), p.8849

2020

Volltextzugriff (PDF)

N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: In vitro, in silico and in vivo evaluation of a multi-target ligand

Neurochemistry international, 2021-06, Vol.146, p.105016-105016, Article 105016

2021

Volltextzugriff (PDF)

Development and Characterization of Novel Selective, Non-Basic Dopamine D 2 Receptor Antagonists for the Treatment of Schizophrenia

Molecules (Basel, Switzerland), 2023-05, Vol.28 (10)

2023

Volltextzugriff (PDF)

Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents – Design, synthesis, structural studies and pharmacological profiling

European journal of medicinal chemistry, 2023-04, Vol.252, p.115285-115285, Article 115285

2023

Volltextzugriff (PDF)

Multitarget Derivatives of D2AAK1 as Potential Antipsychotics: The Effect of Substitution in the Indole Moiety

ChemMedChem, 2022-08, Vol.17 (15), p.e202200238-n/a

2022

Volltextzugriff (PDF)

Discovery and in vitro Evaluation of Novel Serotonin 5-HT 2A Receptor Ligands Identified Through Virtual Screening

ChemMedChem, 2024-07, Vol.19 (14), p.e202400080

2024

Volltextzugriff (PDF)

Development and Characterization of Novel Selective, Non-Basic Dopamine D[sub.2] Receptor Antagonists for the Treatment of Schizophrenia

Molecules (Basel, Switzerland), 2023-05, Vol.28 (10)

2023

Volltextzugriff (PDF)

Analytical method for determining quantum well exciton properties in a magnetic field

Physical review. B, Condensed matter and materials physics, 2015-05, Vol.91 (19), Article 195302

2015

Volltextzugriff (PDF)

Overcoming Depression with 5-HT 2A Receptor Ligands

International journal of molecular sciences, 2021-12, Vol.23 (1)

2021

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Current Concepts and Treatments of Schizophrenia

Multi-Target Approach for Drug Discovery against Schizophrenia

Overcoming Depression with 5-HT2A Receptor Ligands

Screening and Structure-Activity Relationship of D2AAK1 Derivatives for Potential Application in the Treatment of Neurodegenerative Diseases

What are the challenges with multi-targeted drug design for complex diseases?

Tight-binding model for exciton-polariton condensates in external potentials

Effects of small molecules on neurogenesis: Neuronal proliferation and differentiation

Thermal behavior and determination of physicochemical properties of novel candidates for antipsychotic drugs

Experimental and computational structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles

Development and Characterization of Novel Selective, Non-Basic Dopamine D2 Receptor Antagonists for the Treatment of Schizophrenia

Multi-targeted drug design strategies for the treatment of schizophrenia

Current Approaches and Tools Used in Drug Development against Parkinson's Disease

Funnel metadynamics and behavioral studies reveal complex effect of D2AAK1 ligand on anxiety-like processes

Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds-synthesis, biological activity, and structural evaluation

Synthesis, pharmacological and structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as multi-target ligands of aminergic GPCRs

Discovery and in vitro Evaluation of Novel Serotonin 5‐HT2A Receptor Ligands Identified Through Virtual Screening

The Antipsychotic D2AAK1 as a Memory Enhancer for Treatment of Mental and Neurodegenerative Diseases

N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: In vitro, in silico and in vivo evaluation of a multi-target ligand

Development and Characterization of Novel Selective, Non-Basic Dopamine D 2 Receptor Antagonists for the Treatment of Schizophrenia

Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents – Design, synthesis, structural studies and pharmacological profiling

Multitarget Derivatives of D2AAK1 as Potential Antipsychotics: The Effect of Substitution in the Indole Moiety

Discovery and in vitro Evaluation of Novel Serotonin 5-HT 2A Receptor Ligands Identified Through Virtual Screening

Development and Characterization of Novel Selective, Non-Basic Dopamine D[sub.2] Receptor Antagonists for the Treatment of Schizophrenia

Analytical method for determining quantum well exciton properties in a magnetic field

Overcoming Depression with 5-HT 2A Receptor Ligands

Suchergebnisse filtern